CN112057431A

CN112057431A - Vanillan tartrate tablet and preparation method thereof

Info

Publication number: CN112057431A
Application number: CN202011193952.1A
Authority: CN
Inventors: 张春林; 张晓瑜; 宗书敏
Original assignee: Changzhou Hengbang Pharmaceutical Co ltd; Jiangsu Hansoh Pharmaceutical Group Co Ltd
Current assignee: Changzhou Hengbang Pharmaceutical Co ltd; Jiangsu Hansoh Pharmaceutical Group Co Ltd
Priority date: 2020-10-30
Filing date: 2020-10-30
Publication date: 2020-12-11
Anticipated expiration: 2040-10-30
Also published as: CN112057431B

Abstract

The invention provides a tartaric acid varenicline tablet and a preparation method thereof, wherein the composition comprises 5: 1-10: 1 parts by weight of sorbitol and microcrystalline cellulose, and also comprises a disintegrating agent, a binder and a lubricant. The product has simple preparation process, easy operation and good reproducibility, and is suitable for industrial mass production. In addition, the valnemulin tartrate composition prepared by the method does not need to control the particle size, and is small in friability, good in fluidity, high in dissolution rate, good in stability and small in probability of causing adverse reaction.

Description

Vanillan tartrate tablet and preparation method thereof

Technical Field

The invention belongs to the field of pharmaceutical preparations, and particularly relates to a valnemulin tartrate tablet and a preparation method thereof.

Background

Vanillin can specifically bind to acetylcholine receptors and is used to modulate cholinergic function. Thus, the compounds may be used to treat a variety of diseases or conditions, including, but not limited to, inflammatory bowel disease, irritable bowel syndrome, spasmodic dystonia, chronic pain, acute pain, vasoconstriction, anxiety, panic disorder, depression, bipolar disorder, autism, sleep disorders, jet lag, Amyotrophic Lateral Sclerosis (ALS), cognitive disorders, hypertension, bulimia, anorexia, obesity, cardiac arrhythmia, hypersecretion of gastric acid, ulcers, pheochromocytoma, chemical dependencies and cravings (e.g., for nicotine (and/or tobacco products), alcohol, benzodiazepines, barbiturates, opioids or cocaine dependencies or cravings), headache, migraine, stroke, Traumatic Brain Injury (TBI), Obsessive Compulsive Disorder (OCD), psychosis, tardive dyskinesia, hyperkinesia, dyslexia, obsessive compulsive disorder, Schizophrenia, multi-infarct dementia, age-related cognitive decline, epilepsy, including seizures, senile dementia of the alzheimer type (AD), Parkinson's Disease (PD), Attention Deficit Hyperactivity Disorder (ADHD), and tourette's syndrome. Varenicline tartrate is a smoking cessation drug developed by the company pfeir which is effective in alleviating craving and withdrawal symptoms of nicotine and helps to reduce the pleasure of smoking in 12-week treatment. Vanillan tartrate is an FDA approved drug for assisting smoking cessation and has the following specific structure:

vanillan is a highly potent compound, generally used in low doses, and such pharmaceutical substances are usually formulated in high dilution,

however, unique challenges are introduced in the preparation and storage of such diluted formulations. Because this may cause significant degradation of the excipient or even impurities of the excipient during storage or differences in efficacy due to segregation and drag of the equipment during production. Also, solubility, high temperature, high humidity, light and oxidation stability are issues that must be considered in the formulation.

CN101535310A discloses two impurities present in vannemine, i.e. N-formylvannemine and N-carboxyvannemine, the specific structures of which are as follows:

patent WO2004103372A discloses that varenicline formulations exhibit two degradation impurities during storage, namely N-methyl varenicline and N-formyl varenicline, wherein the structure of the N-methyl varenicline impurity is as follows:

WO2006117672A discloses arylamino impurities common in vannemilan, which have the following structure:

CN107753449A discloses a varenicline tablet composition, but the application needs to control the particle size of varenicline tartrate to be a certain size, the process is complicated and the cost is high, and sodium dodecyl sulfate is required to be added, but the sodium dodecyl sulfate has toxicity to human bodies, has great side effect and is not suitable for long-term administration.

Therefore, in order to solve the problems that the dissolution rate of the valnemulin tartrate tablet is reduced along with the prolonging of the time and impurities are easy to generate in the storage process, the valnemulin tartrate preparation which has the advantages of high dissolution rate, good stability, small impurity content, simple process and convenient operation needs to be developed.

Disclosure of Invention

The invention aims to overcome the defects of the prior art and provide a valnemulin tartrate tablet which has high dissolution rate, high stability, small specific impurity content, simple operation and easy industrial production.

In one aspect, the invention provides a valnemulin tartrate tablet which comprises a tablet core and a coating.

In a preferred embodiment of the invention, the tablet core comprises one or more of a diluent, a binder, a disintegrant or a lubricant.

In a further preferred embodiment of the invention, the diluent is sorbitol and microcrystalline cellulose, and the weight percentage of the sorbitol and the microcrystalline cellulose is 5: 1-10: 1.

In a further preferred embodiment of the invention, the weight percentage of sorbitol to microcrystalline cellulose is 9: 1.

In a further preferred embodiment of the invention, wherein the binder is selected from one or more of hydroxypropyl cellulose, methyl cellulose, sodium carboxymethyl cellulose or polyvinylpyrrolidone; preferably one or two of hydroxypropyl cellulose or polyvinylpyrrolidone; more preferably polyvinylpyrrolidone.

In a further preferred embodiment of the present invention, wherein the disintegrant is selected from one or more of croscarmellose sodium, sodium carboxymethyl starch, low substituted hydroxypropyl cellulose, or crospovidone; preferably one or more of croscarmellose sodium, low substituted hydroxypropyl cellulose or crospovidone; more preferred is low-substituted hydroxypropylcellulose.

In a further preferred embodiment of the invention, wherein the lubricant is selected from one or more of magnesium stearate, talc, aerosil or silica; preferably one or more of magnesium stearate, aerosil or silicon dioxide; more preferably magnesium stearate.

In a further preferred embodiment of the invention, the coating is of the gastro-soluble type, the coating weight gain being between 3% and 6% (in weight percentage of the tablet core).

In a further preferred embodiment of the present invention, wherein the weight percentage content of the tartaric acid ester of varenicline is 0.5% -1.5%; the weight percentage content of the sorbitol and the microcrystalline cellulose is 90-96%; the weight percentage content of the adhesive is 2% -4%; the weight percentage content of the disintegrating agent is 1% -4%; the weight percentage of the lubricant is 0.5% -1%.

In a further preferred embodiment of the invention, wherein the weight percentage content of the tartaric acid varenicline is 0.8% -1.2%; the weight percentage content of the sorbitol and the microcrystalline cellulose is 92-95%; the weight percentage content of the adhesive is 2% -3%; the weight percentage content of the disintegrating agent is 1% -3%; the weight percentage content of the lubricant is 0.5% -0.8%.

In a further preferred embodiment of the invention, wherein the weight percentage of the valnemadex tartrate is 1%; the weight percentage content of the sorbitol and the microcrystalline cellulose is 95 percent; the weight percentage content of the adhesive is 2 percent; the weight percentage content of the disintegrating agent is 1.5 percent; the weight percentage of the lubricant is 0.5 percent.

In a further preferred embodiment of the invention, the coating layer comprises one or more of a film-forming agent, a plasticizer, an opacifier or a colorant.

In a further preferred embodiment of the present invention, the film forming agent is selected from one or two of ethyl cellulose, hypromellose; the plasticizer is selected from one or more of propylene glycol, glycerol, polyethylene glycol and polyvinyl alcohol; the opacifier is one or two of talcum powder or titanium dioxide; the colorant is one or two selected from red ferric oxide, yellow ferric oxide or indigo.

In a further preferred embodiment of the invention the tablets of varenicline tartrate comprise 0.5mg or 1.0mg of the specification (by weight of the free base of varenicline).

In a further preferred embodiment of the present invention, the hardness of the tablets of varenicline tartrate is controlled to be 3 to 10 Kp.

On the other hand, the invention aims to provide a preparation method of the valnemulin tartrate tablet, which comprises the following steps:

1) mixing part of the lubricant, microcrystalline cellulose and varenicline tartrate, sieving, and grading to obtain a mixture;

2) uniformly mixing the mixture obtained in the step 1) with sorbitol, a binder and a disintegrating agent;

3) adding the rest of the lubricant into the mixture obtained in the step 2), and uniformly mixing;

4) tabletting the total mixed particles obtained in the step 3);

5) coating the compressed tablets obtained in the step 4).

In a preferred embodiment, the method is carried out,

1) mixing part of lubricant, microcrystalline cellulose and varenicline tartrate at the rotation speed of 15rpm for 20 minutes, sieving and granulating, wherein the mesh size is 0.8-2.0mm during granulating, and preparing into a mixture;

2) mixing the mixture obtained in the step 1) with sorbitol, a binder and a disintegrating agent for 10-30 minutes at the rotating speed of 15 rpm;

3) adding the rest of the lubricant into the mixture obtained in the step 2), and mixing for 10-20 minutes at the rotating speed of 15 rpm;

4) tabletting the total mixed particles obtained in the step 3), and controlling the hardness of the tablets to be 3-10 Kp;

5) coating the compressed tablets obtained in the step 4).

In a more preferred embodiment, the process is carried out,

1) mixing part of magnesium stearate, microcrystalline cellulose and varenicline tartrate at the rotation speed of 15rpm for 20 minutes, sieving, and grading, wherein the mesh size is 0.8-2.0mm during grading, to obtain mixture;

2) mixing the mixture obtained in the step 1) with sorbitol, polyvinylpyrrolidone and low-substituted hydroxypropyl cellulose for 10-30 minutes at the rotating speed of 15 rpm;

3) adding the rest magnesium stearate into the mixture obtained in the step 2), and mixing for 10-20 minutes at the rotating speed of 15 rpm;

5) coating the compressed tablets obtained in the step 4), wherein the coating material comprises hydroxypropyl methylcellulose and propylene glycol, and optionally one or two of titanium dioxide, red ferric oxide or indigo; the coating solvent is water, and the weight of the coating is increased by 3-6%.

The invention has the advantages that the preparation method is simple, the particle size does not need to be strictly controlled, and the valnemulin tartrate tablet which is toxic to human bodies does not need to be added, and has the advantages of small friability, good fluidity, high dissolution rate, good stability, small content of specific impurities and less side reactions such as nausea and vomiting.

Detailed Description

To further illustrate the present invention, the present invention will be specifically described with reference to specific examples, but the scope of the present invention is not limited to the specific examples.

Example 1

1) Mixing one third of magnesium stearate, microcrystalline cellulose and varenicline tartrate at 15rpm for 20 minutes, sieving, and grading, wherein the mesh size is 0.8-2.0mm during grading, to obtain mixture;

2) mixing the mixture obtained in the step 1) with mannitol, polyvinylpyrrolidone and low-substituted hydroxypropyl cellulose at the rotating speed of 15rpm for 10-30 minutes;

5) transferring the pressed plain tablets in the step 4) to a coating machine for coating operation.

Example 2

2) mixing the mixture obtained in the step 1) with calcium hydrophosphate, polyvinylpyrrolidone and low-substituted hydroxypropyl cellulose for 10-30 minutes at the rotating speed of 15 rpm;

Example 3

Example 4

The preparation method refers to example 3.

Example 5

The preparation method refers to example 3.

Example 6

2) mixing the mixture obtained in the step 1) with sorbitol, polyvinylpyrrolidone and croscarmellose sodium for 10-30 minutes at the rotating speed of 15 rpm;

Example 7

2) mixing the mixture obtained in the step 1) with sorbitol, polyvinylpyrrolidone and crospovidone for 10-30 minutes at the rotating speed of 15 rpm;

Example 8

2) mixing the mixture obtained in the step 1) with sorbitol and low-substituted hydroxypropyl cellulose for 10-30 minutes at the rotating speed of 15 rpm;

Example 9

The preparation method refers to example 3.

Example 10

EXAMPLE 11 Raney tartrate tablet friability, flowability testing

Angle of repose test: the angle of repose of the particles is determined by a fixed funnel method, specifically, a 6cm glass funnel is vertically fixed, and the lower end of the funnel is 50mm away from a table top. And (3) allowing the particles to freely flow out of the funnel to a piece of coordinate paper, so that the particles are stacked into a cone shape until the particles just contact with the lower end of the funnel, and recording the edge line of the bottom surface of the cone. The ratio of the height (50mm) of the cone to the radius of the bottom surface of the cone is used for solving the inverse tangent function, and the repose angle of the particle is obtained.

Angle of repose of the granules = arctg (50/radius of the base of the cone mm)

And (3) brittle degree inspection: the weight loss reduction amount (%) is calculated according to a method under the item of ' tablet friability inspection method ' in the appendix XG of the second part of the pharmacopoeia of the people's republic of China, edition 2010, and whether the tablet has abnormal conditions such as fracture, crack and/or crushing is observed.

TABLE 1

From the results in table 1, it is clear that when the kind of diluent in the recipe is changed, the angle of repose of the valnemulin tartrate composition is large, the fluidity is poor, and the friability is large, as compared with examples 1 and 2 and example 3; as can be seen from the comparison between examples 6 and 8 and example 3, when the type of disintegrant or binder in the formulation is changed, the tartaric acid varenicline composition has a large angle of repose, a poor flowability, and a large friability; as is clear from example 10 compared with example 3, when the proportion of the diluent was changed, the angle of repose of the valnemulin tartrate composition was large, the flowability was poor, and the friability was large. From the results of table 1, it can be seen that the type and proportion of the diluent, and the type of the disintegrant and binder have a very important influence on the flowability and friability of the tartronic composition.

EXAMPLE 12 Vanillan tartrate tablet dissolution test

Referring to the second method of XC paddle method in the appendix of the second part of the 2010 version of the Chinese pharmacopoeia, the stirring speed is 75rpm, and the dissolution medium is 900mL of pH4.5 buffer solution. The dissolution results were as follows:

TABLE 2

From the results in table 2, it can be seen that the dissolution of the valnemulin tartrate composition is significantly reduced when the kind of diluent in the prescription is changed as compared with example 3 in examples 1 and 2; as can be seen from the comparison of examples 6 and 8 with example 3, the dissolution rate of the valnemulin tartrate composition is obviously reduced when the type of disintegrant or the binder in the prescription is changed; it can be seen from example 10 that the dissolution of the valnemulin tartrate composition is significantly reduced by varying the proportion of diluent as compared to example 3. From the results of table 2, it can be seen that the type and ratio of the diluent, and the type of disintegrant and binder have a very important effect on the dissolution of the valnemulin composition.

EXAMPLE 13 Valnemulin tartrate tablet stability testing

NMV is N-methylVanillan as a particular impurity, NFV is N-formylVanillan as a particular impurity, and NCF is N-carboxyVanillan as a particular impurity.

(1) Respectively placing the sample at 60 deg.C, 25 deg.C/RH 90%, and illuminating (total illumination is not less than 1.2 × 10)⁶Lux hr) at 5d and 10d respectively, and comparing with 0d, the test result is as follows:

TABLE 3

From the results of table 3, it is clear that when the kind of diluent in the formulation is changed, the contents of the impurities NMV, NFV and NCF are significantly increased under high temperature, high humidity or light conditions, as compared with examples 1, 2 and 3; as can be seen from comparison of examples 6 and 8 with example 3, when the kind of disintegrant or the binder in the formulation was changed, the contents of impurities NMV, NFV and NCF were significantly increased under high temperature, high humidity or light conditions; as is clear from example 10 compared with example 3, when the proportion of the diluent was changed, the contents of the impurities NMV, NFV and NCF were significantly increased under high temperature, high humidity or light conditions. From the results of table 3, it is understood that the type and ratio of the diluent, and the type of the disintegrant and the binder have a very important influence on the stability of the formulation under high temperature, high humidity and light conditions.

(2) The samples were placed at 40 ℃. + -. 2 ℃/RH 75%. + -. 5% and sampled at 1M, 2M, 3M, 6M respectively for testing, and compared with the 0M results, the test results were as follows:

TABLE 4

From the results of Table 4, it is clear that when the types of diluents in the formulations were changed, the contents of NMV, NFV and NCF as impurities were significantly increased when the formulations were left for a long period of time at 40 ℃. + -. 2 ℃/RH 75%. + -. 5%, as compared with examples 1 and 2 and 3; as can be seen from comparison of examples 6 and 8 with example 3, when the type of disintegrant or the binder in the formulation is changed, the contents of NMV, NFV and NCF as impurities are significantly increased when the composition is left for a long time under the condition of 40 ℃. + -. 2 ℃/RH 75%. + -. 5%; it is clear from example 10 compared to example 3 that, when the proportion of the diluent is changed, the contents of the impurities NMV, NFV and NCF are significantly increased when the composition is left for a long time under the condition of 40 ℃ ± 2 ℃/RH75% ± 5%. From the results in Table 4, it can be seen that the type and ratio of the diluent, the type of disintegrant and the binder have a very important effect on the long-term stability of the formulation at 40 ℃. + -. 2 ℃/RH 75%. + -. 5%.

(2) The sample is placed under the conditions of 30 ℃ plus or minus 2 ℃/RH 65 percent plus or minus 5 percent, and is sampled and detected at 3M, 6M and 9M respectively, and compared with the 0M result, the test result is as follows:

TABLE 5

From the results of Table 5, it is clear that when the types of diluents in the recipe are changed, the contents of NMV, NFV and NCF as impurities are remarkably increased when the composition is left for a long time under the condition of 30 ℃. + -. 2 ℃/RH 65%. + -. 5%; as can be seen from comparison of examples 6 and 8 with example 3, when the type of disintegrant or binder in the formulation is changed, the contents of NMV, NFV and NCF as impurities are significantly increased when the composition is left for a long time under the condition of 30 ℃. + -. 2 ℃/RH 65%. + -. 5%; it is understood from example 10 that, when the proportion of the diluent is changed, the contents of NMV, NFV and NCF as impurities are remarkably increased when the composition is left for a long time under the condition of 30 ℃. + -. 2 ℃/RH 65%. + -. 5%. From the results of Table 5, it can be seen that the type and ratio of the diluent, the type of disintegrant and the binder have a very important effect on the long-term stability of the formulation at 30 ℃. + -. 2 ℃/RH 65%. + -. 5%.

EXAMPLE 14 tablet side reaction testing of Vanillan tartrate

Establishing an SD rat smoking model: SD rats of 110 males and females were randomly divided into 11 groups of 10 animals each, and used as a blank control group and a test group. Wherein, the rats in the test group are placed in an aeration cabinet, cigarettes (2 times/day, 16 times/time) are given smoke exposure environment, the smoke concentration in the cabinet is controlled to be about 7 percent, the duration of each smoke exposure is 30 minutes, the interval time of each smoking is 4 hours, and the continuous period is 75 days. Rats were then gavaged with varenicline tartrate, formulated 1-10 of the above examples, at a dose of 0.06 mg/kg/dose for 2 weeks. The placebo group was gavaged at the same time point with 0.9% NaCl. After administration, each rat was observed for the incidence of adverse reactions such as nausea and vomiting. The results are as follows:

TABLE 6

From the results in table 6, it is clear that, when the diluent type in the prescription is changed, the probability of the rat suffering from adverse reactions such as nausea and vomiting is remarkably increased as compared with examples 1 and 2 and 3; as can be seen from comparison between examples 6 and 8 and example 3, when the type of disintegrant or binder in the prescription is changed, the probability of adverse reactions such as nausea and vomiting of rats is obviously increased; as is clear from example 10 and example 3, when the ratio of the diluent was changed, the probability of the adverse reactions such as nausea and vomiting in the rats was significantly increased. From the results shown in Table 6, it is understood that the type and ratio of the diluent and the type of the disintegrant and the binder have a very important influence on the probability of the occurrence of adverse reactions such as nausea and vomiting in rats.

In conclusion, the valnemulin tartrate composition prepared by the invention does not need to control the particle size, is simple in prescription, has smaller friability, better fluidity, higher dissolution and higher stability, and has smaller probability of side reactions of nausea and vomiting.

Claims

1. The tablet is characterized by comprising a tablet core and a coating, wherein the tablet core contains one or more of diluent, adhesive, disintegrant or lubricant, the diluent is sorbitol and microcrystalline cellulose, the weight percentage of the sorbitol and the microcrystalline cellulose is 5: 1-10: 1, the adhesive is selected from one or more of hydroxypropyl cellulose, methyl cellulose, sodium carboxymethyl cellulose or polyvinylpyrrolidone, the disintegrant is selected from one or more of croscarmellose sodium, sodium carboxymethyl starch, low-substituted hydroxypropyl cellulose or crospovidone, and the lubricant is selected from one or more of magnesium stearate, talcum powder, micropowder silica gel or silicon dioxide; the coating is gastric soluble, and the weight of the coating is increased by 3 to 6 percent.

2. The valnemulin tartrate tablet according to claim 1, wherein the weight percentage of sorbitol to microcrystalline cellulose is 9: 1.

3. The valnemulin tartrate tablet according to claim 1, wherein the valnemulin tartrate is present in an amount of from 0.5% to 1.5% by weight; the weight percentage content of the sorbitol and the microcrystalline cellulose is 90-96%; the weight percentage content of the adhesive is 2% -4%; the weight percentage content of the disintegrating agent is 1% -4%; the weight percentage of the lubricant is 0.5% -1%.

4. The valnemulin tartrate tablet according to claim 3, wherein the valnemulin tartrate is present in an amount of from 0.8% to 1.2% by weight; the weight percentage content of the sorbitol and the microcrystalline cellulose is 92-95%; the weight percentage content of the adhesive is 2% -3%; the weight percentage content of the disintegrating agent is 1% -3%; the weight percentage content of the lubricant is 0.5% -0.8%.

5. The valnemulin tartrate tablet according to claim 3, wherein the valnemulin tartrate is present in an amount of 1% by weight; the weight percentage content of the sorbitol and the microcrystalline cellulose is 95 percent; the weight percentage content of the adhesive is 2 percent; the weight percentage content of the disintegrating agent is 1.5 percent; the weight percentage of the lubricant is 0.5 percent.

6. The valnemulin tartrate tablet according to claim 1, wherein the coating comprises one or more of a film forming agent, a plasticizer, an opacifier or a colorant.

7. The valnemulin tartrate tablet according to claim 6, wherein the film forming agent is selected from one or both of ethylcellulose and hypromellose; the plasticizer is selected from one or more of propylene glycol, glycerol, polyethylene glycol and polyvinyl alcohol; the opacifier is one or two of talcum powder or titanium dioxide; the colorant is one or two selected from red ferric oxide, yellow ferric oxide or indigo.

8. The valnemulin tartrate tablet according to claim 1, wherein the valnemulin tartrate tablet comprises a 0.5mg or 1.0mg format.

9. The valnemulin tartrate tablet according to claim 1, wherein the hardness of the valnemulin tartrate tablet is 3 to 10 Kp.

10. The preparation of the valnemulin tartrate tablets according to any one of claims 1 to 9, characterised in that the steps are as follows:

4) tabletting the total mixed particles obtained in the step 3);

5) coating the compressed tablets obtained in the step 4).